HomeCompareRCDTF vs ORCC

RCDTF vs ORCC: Dividend Comparison 2026

RCDTF yields 2.77% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RCDTF wins by $31.2K in total portfolio value· pulled ahead in Year 2
10 years
RCDTF
RCDTF
● Live price
2.77%
Share price
$56.95
Annual div
$1.58
5Y div CAGR
32%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.6K
Annual income
$9,708.55
Full RCDTF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — RCDTF vs ORCC

📍 RCDTF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRCDTFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RCDTF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RCDTF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RCDTF
Annual income on $10K today (after 15% tax)
$235.82/yr
After 10yr DRIP, annual income (after tax)
$8,252.27/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, RCDTF beats the other by $8,251.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RCDTF + ORCC for your $10,000?

RCDTF: 50%ORCC: 50%
100% ORCC50/50100% RCDTF
Portfolio after 10yr
$37.0K
Annual income
$4,854.80/yr
Blended yield
13.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

RCDTF
Analyst Ratings
2
Hold
1
Sell
Consensus: Hold
Altman Z
3.4
Piotroski
5/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RCDTF buys
0
ORCC buys
0
No recent congressional trades found for RCDTF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRCDTFORCC
Forward yield2.77%9.79%
Annual dividend / share$1.58$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR32%-50%
Portfolio after 10y$52.6K$21.4K
Annual income after 10y$9,708.55$1.04
Total dividends collected$28.6K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: RCDTF vs ORCC ($10,000, DRIP)

YearRCDTF PortfolioRCDTF Income/yrORCC PortfolioORCC Income/yrGap
1$11,066$366.22$11,190$489.61$124.00ORCC
2← crossover$12,341$499.95$12,229$256.01+$112.00RCDTF
3$13,892$687.80$13,216$130.74+$676.00RCDTF
4$15,820$955.18$14,207$66.02+$1.6KRCDTF
5$18,269$1,341.86$15,234$33.17+$3.0KRCDTF
6$21,460$1,911.67$16,317$16.62+$5.1KRCDTF
7$25,732$2,770.17$17,468$8.32+$8.3KRCDTF
8$31,631$4,097.76$18,695$4.16+$12.9KRCDTF
9$40,060$6,214.06$20,006$2.08+$20.1KRCDTF
10$52,572$9,708.55$21,407$1.04+$31.2KRCDTF

RCDTF vs ORCC: Complete Analysis 2026

RCDTFStock

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Full RCDTF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this RCDTF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RCDTF vs SCHDRCDTF vs JEPIRCDTF vs ORCDTF vs KORCDTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.